Recombinate shortage status
1 active shortage notice across 1 country.
Last updated 1 Aug 2026 · sourced from official medicines regulators
- Generic name (INN)
- Recombinate
- Brand names
- RECOMBINATE, [Antihemophilic Factor ]
- Class
- Auto-created by FDA MedWatch — Drug Safety Alerts scraper
Where Recombinate is in shortage
| Country | Severity | Notices | Since | Est. resolution | Source |
|---|---|---|---|---|---|
| United States | high | 1 | 30 Jul 2025 | — | FDA MedWatch |
Why Recombinate is in shortage
- regulatory action — e.g. “CGMP Deviations - Product was exposed to temperatures outside the product's labeled storage requirements.” (United States)
Frequently asked questions
Is Recombinate currently in shortage?
Yes. As of the latest regulator updates, Recombinate has 1 active shortage notice across 1 country (United States). Status is refreshed daily from official regulatory sources.
Why is Recombinate in shortage?
Regulators attribute the current Recombinate shortages to regulatory action. The exact cause varies by country and product — each notice on this page links to the official source.
Where does this Recombinate shortage data come from?
Every shortage notice on this page is scraped daily from an official national medicines regulator (such as the FDA, TGA, MHRA or EMA) and linked back to its source. Mederti aggregates 40+ regulators across 50+ countries and never publishes unsourced shortage claims.
Get alerted when Recombinate status changes
Free for individual pharmacists and clinicians — watchlists, email alerts, alternatives and country-by-country product detail.
Create a free accountData on this page is aggregated from official national medicines regulators and updated daily. It is provided for information only and requires verification before clinical use. Mederti is not affiliated with or endorsed by any regulator.